AbstralTM continues strong development of over 40 percent in first-quarter 2010 Orexo Abdominal today confirms that its partner, ProStrakan Group plc has announced that AbstralTM continues to show strong sales development in 2010 2010.8 million in its first year available tadalafil .0 million. The successful establishment in each one of the countries in which it has been launched can be demonstrated by the following market shares : France 27 percent; Germany 20 percent; Spain 10 percent; Sweden 69 percent; and UK 21 percent. There is also evidence of a significant increase in the size of the market for fentanyl-based products for breakthrough cancer pain across the major EU-countries in which ProStrakan operates .
The Associated Press/Washington Post: Accenture Predicts Growth Surge For Retail Wellness Treatment centers As Overhaul Adds Covered Patients The amount of retail health treatment centers that have been showing up in places like drugstores for a long time is likely to double by the end of 2015, based on the consulting company Accenture. Accenture said in a written report released Wednesday that a flood of recently insured individuals from the national healthcare overhaul can help stoke demand for those treatment centers, which typically treat minor illnesses when a individual doesn't have a doctor or the doctor isn't available .